| Literature DB >> 35542055 |
Jun-Wei He1, Li Yang2, Zhen-Qiang Mu3, Yu-Ye Zhu1, Guo-Yue Zhong1, Zhi-Yong Liu4, Qing-Guang Zhou1, Fang Cheng1.
Abstract
Hosta plantaginea was a traditional Chinese medicinal plant used to treat inflammation-related diseases with little scientific validation. Twelve flavonoids, including two new compounds namely plantanones A (1) and B (2), were isolated from the flowers of Hosta plantaginea. Their structures were elucidated by NMR and HRMS as well as comparison with literature data. All of the isolated compounds showed significant inhibitory activities against ovine COX-1 and COX-2 at a concentration of 50 μM, with inhibition ratios from 53.00% to 80.55% for COX-1 and from 52.19% to 66.29% for COX-2. Further detailed testing showed that compounds 1, 2, 4 and 12 inhibited the COX-1 and COX-2 enzymes with IC50 values 12.90-33.37 μM and 38.32-46.16 μM, respectively. Moreover, the antioxidant effects of these isolates against DPPH free radical-scavenging were also evaluated in vitro, and a tight structure-activity relationship was discussed. Our results suggested that the anti-inflammatory and antioxidant activities of H. plantaginea flowers are partly attributed to these flavonoids. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35542055 PMCID: PMC9080520 DOI: 10.1039/c8ra00443a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Chemical structures of compounds 1–12.
1H and 13C NMR data for 1 in DMSO-d6 (δ in ppm, J in Hz)
| No. |
|
| No. |
|
|
|---|---|---|---|---|---|
| 2 | 156.2 | — | 3′′ | 77.5 | 3.06–3.10 (3H, m) |
| 3 | 133.1 | — | 4′′ | 69.7 | 3.12–3.17 (2H, m) |
| 4 | 177.6 | — | 5′′ | 76.6 | 3.46–3.52 (4H, m) |
| 4a | 104.9 | — | 6′′ | 60.8 | 3.60 (1H, |
| 5 | 160.9 | — | 3.46–3.52 (4H, m) | ||
| 6 | 97.9 | 6.36 (1H, | Glc 2 | ||
| 7 | 165.0 | — | 1′′′ | 104.1 | 4.62 (1H, |
| 8 | 92.2 | 6.74 (1H, | 2′′′ | 74.4 | 3.06–3.10 (3H, m) |
| 8a | 155.9 | — | 3′′′ | 77.0 | 3.12–3.17 (2H, m) |
| 1′ | 120.8 | — | 4′′′ | 69.6 | 3.06–3.10 (3H, m) |
| 2′, 6′ | 131.0 | 8.08–8.10 (2H, | 5′′′ | 76.7 | 3.18 (1H, m) |
| 3′, 5′ | 115.3 | 6.91–6.93 (2H, | 6′′′ | 60.5 | 3.46–3.52 (4H, m) |
| 4′ | 160.1 | — | 3.26 (1H, m) | ||
| Glc 1 | 5-OH | — | 12.65 (1H, s) | ||
| 1′′ | 97.9 | 5.72 (1H, | 4′-OH | — | 10.22 (1H, s) |
| 2′′ | 82.4 | 3.46–3.52 (4H, m) | 7-OMe | 56.1 | 3.86 (3H, s) |
Fig. 2The selected 1H–1H COSY and HMBC correlations of compounds 1 and 2.
1H and 13C NMR data for 2 in DMSO-d6 (δ in ppm, J in Hz)
| No. |
|
| No. |
|
|
|---|---|---|---|---|---|
| 2 | 156.7 | — | 6′′ | 66.6 | 3.67–3.71 (2H, m) |
| 3 | 133.1 | — | 3.33–3.35 (2H, m) | ||
| 4 | 177.3 | — | Rha | ||
| 4a | 104.0 | — | 1′′′ | 100.8 | 4.37–4.40 (2H, m) |
| 5 | 161.2 | — | 2′′′ | 70.4 | 3.26–3.29 (2H, m) |
| 6 | 98.8 | 6.20 (1H, br.s) | 3′′′ | 70.2 | 3.38–3.40 (3H, m) |
| 7 | 164.2 | — | 4′′′ | 71.8 | 3.09 (1H, m) |
| 8 | 93.8 | 6.41 (1H, br.s) | 5′′′ | 68.4 | 3.17–3.22 (3H, m) |
| 8a | 156.5 | — | 6′′′ | 17.8 | 0.98 (3H, |
| 1′ | 120.9 | — | Glc 2 | ||
| 2′, 6′ | 130.9 | 7.95–8.00 (2H, | 1′′′′ | 104.0 | 4.37–4.40 (2H, m) |
| 3′, 5′ | 115.2 | 6.87–6.90 (2H, | 2′′′′ | 73.9 | 3.38–3.40 (3H, m) |
| 4′ | 159.9 | — | 3′′′′ | 76.2 | 3.17–3.22 (3H, m) |
| Glc 1 | 4′′′′ | 70.6 | 3.04–3.08 (2H, m) | ||
| 1′′ | 100.4 | 5.44 (1H, | 5′′′′ | 76.9 | 3.17–3.22 (3H, m) |
| 2′′ | 86.9 | 3.48 (1H, m) | 6′′′′ | 61.1 | 3.67–3.71 (2H, m) |
| 3′′ | 73.1 | 3.04–3.08 (2H, m) | 3.38–3.40 (3H, m) | ||
| 4′′ | 68.4 | 3.26–3.29 (2H, m) | 5-OH | — | 12.58 (1H, br.s) |
| 5′′ | 75.3 | 3.33–3.35 (2H, m) | 7-OH | — | 10.85 (1H, br.s) |
| 4′-OH | — | 10.18 (1H, br.s) |
Inhibitory activity of compounds 1–12 on COX assay
| Comp. | Inhibitions | IC50 (μM) | SI | ||
|---|---|---|---|---|---|
| COX-1 | COX-2 | COX-1 | COX-2 | ||
| 1 | 62.56 ± 0.56 | 56.24 ± 0.43 | 33.37 ± 0.28 | 46.16 ± 0.41 | 0.72 |
| 2 | 76.18 ± 0.62 | 57.70 ± 0.51 | 21.78 ± 0.20 | 44.01 ± 0.42 | 0.49 |
| 3 | 61.10 ± 0.47 | 52.67 ± 0.49 | — | — | — |
| 4 | 72.61 ± 0.71 | 53.81 ± 0.52 | 12.90 ± 0.11 | 45.21 ± 0.43 | 0.28 |
| 5 | 61.43 ± 0.35 | 52.19 ± 0.26 | — | — | — |
| 6 | 66.94 ± 0.45 | 55.11 ± 0.42 | — | — | — |
| 7 | 58.83 ± 0.36 | 66.29 ± 0.38 | — | — | — |
| 8 | 62.88 ± 0.54 | 54.78 ± 0.51 | — | — | — |
| 9 | 53.00 ± 0.41 | 57.54 ± 0.50 | — | — | — |
| 10 | 53.32 ± 0.35 | 57.54 ± 0.32 | — | — | — |
| 11 | 55.43 ± 0.38 | 58.35 ± 0.39 | — | — | — |
| 12 | 80.55 ± 0.42 | 60.78 ± 0.51 | 20.74 ± 0.41 | 38.32 ± 0.34 | 0.54 |
| Celecoxib | — | — | 9.00 ± 0.60 | 1.04 ± 0.10 | 8.65 |
Inhibition (%) values were tested at 50 μM and expressed as the mean S.D. (n = 3).
SI (Selectivity Index) = IC50 (COX-1)/IC50 (COX-2).
Antioxidant activity of compounds 1–12
| Comp. | IC50 (μM) | Compounds | IC50 (μM) | Compounds | IC50 (μM) |
|---|---|---|---|---|---|
| 1 | 467.7 ± 17.9 | 5 | 36.3 ± 1.1 | 9 | 398.1 ± 26.3 |
| 2 | 169.8 ± 5.2 | 6 | 100.0 ± 3.2 | 10 | 208.9 ± 7.3 |
| 3 | 195.0 ± 9.2 | 7 | 77.6 ± 2.4 | 11 | 128.8 ± 9.2 |
| 4 | 257.0 ± 19.9 | 8 | 407.4 ± 22.1 | 12 | 302.0 ± 15.1 |
|
| 33.9 ± 1.1 |